Efficacy and Tolerability of Perampanel in Brain Tumor-Related Epilepsy: A Systematic Review
Authors:
- Jessica RossiJRJessica Rossi
- Francesco CavallieriFCFrancesco Cavallieri
- Maria Chiara BassiMBMaria Chiara Bassi
- Giuseppe BiaginiGiuseppe Biagini
- Romana RizziRRRomana Rizzi
- Marco RussoMRMarco Russo
- Massimo BondavalliMBMassimo Bondavalli
- Corrado IaccarinoCICorrado Iaccarino
- Giacomo PavesiGPGiacomo Pavesi
- Salvatore CozziSCSalvatore Cozzi
- Lucia GiaccheriniLGLucia Giaccherini
- Masoumeh NajafiMNMasoumeh Najafi
Open Access
- 21 February 2023
- journal article
- review article
- Published by MDPI AG in Biomedicines
- Vol. 11 (3) , 651
Abstract
(1) Background: Epilepsy is a frequent comorbidity in patients with brain tumors, in whom seizures are often drug-resistant. Current evidence suggests that excess of glutamatergic activity in the tumor microenvironment may favor epileptogenesis, but also tumor growth and invasiveness. The selective non-competitive α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor antagonist perampanel (PER) was demonstrated to be efficacious and well-tolerated in patients with focal seizures. Moreover, preclinical in vitro studies suggested a potential anti-tumor activity of this drug. In this systematic review, the clinical evidence on the efficacy and tolerability of PER in brain tumor-related epilepsy (BTRE) is summarized. (2) Methods: Five databases and two clinical trial registries were searched from inception to December 2022. (3) Results: Seven studies and six clinical trials were included. Sample size ranged from 8 to 36 patients, who received add-on PER (mean dosage from 4 to 7 mg/day) for BTRE. After a 6–12 month follow-up, the responder rate (% of patients achieving seizure freedom or reduction ≥ 50% of seizure frequency) ranged from 75% to 95%, with a seizure freedom rate of up to 94%. Regarding tolerability, 11–52% of patients experienced non-severe adverse effects (most frequent: dizziness, vertigo, anxiety, irritability). The retention rate ranged from 56% to 83%. However, only up to 12.5% of patients discontinued the drug because of the adverse events. (4) Conclusions: PER seems to be efficacious, safe, and well-tolerated in patients with BTRE. Further randomized studies should be conducted in more homogeneous and larger populations, also evaluating the effect of PER on tumor progression, overall survival, and progression-free survival.Keywords
Funding Information
- Italian Ministry of Health–Ricerca Corrente Annual Program 2023 (EURONANOMED2019-75/GLIOSILK)
- European Innovative Research & Technological Development Projects (EURONANOMED2019-75/GLIOSILK)
- University of Modena and Reggio Emilia (EURONANOMED2019-75/GLIOSILK)
This publication has 27 references indexed in Scilit:
- Seizure response to perampanel in drug-resistant epilepsy with gliomas: early observationsJournal of Neuro-Oncology, 2017
- Perampanel for focal epilepsy: insights from early clinical experienceActa Neurologica Scandinavica, 2015
- Perampanel efficacy and safety by gender: Subanalysis of phase III randomized clinical studies in subjects with partial seizuresEpilepsia, 2015
- Long‐term safety of perampanel and seizure outcomes in refractory partial‐onset seizures and secondarily generalized seizures: Results from phase III extension study 307Epilepsia, 2014
- Tumoral epileptogenicity: How does it happen?Epilepsia, 2013
- Efficacy and safety of adjunctive perampanel for the treatment of refractory partial seizures: A pooled analysis of three phase III studiesEpilepsia, 2013
- Evaluation of adjunctive perampanel in patients with refractory partial‐onset seizures: Results of randomized global phase III study 305Epilepsia, 2012
- Adjunctive perampanel for refractory partial-onset seizuresNeurology, 2012
- Brain Tumor-Related EpilepsyCurrent Neuropharmacology, 2012
- Randomized phase III study 306Neurology, 2012